Valuation: Omeros Corporation

Market Cap 672M 587M 540M 503M 954M 63.95B 968M 6.48B 2.52B 31.43B 2.52B 2.47B 108B P/E 2026 *
28.1x
P/E 2027 * -33.1x
Enterprise Value 672M 587M 540M 503M 954M 63.95B 968M 6.48B 2.52B 31.43B 2.52B 2.47B 108B EV / Sales 2026 *
9.9x
EV / Sales 2027 * 4.69x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day-1.38%
1 week+7.04%
Current month-2.42%
1 month-9.46%
3 months-14.86%
6 months-43.35%
Current year-45.97%
1 week 8.52
Extreme 8.517
10.16
1 month 6.7
Extreme 6.7023
10.83
Current year 6.7
Extreme 6.7023
17.63
1 year 3
Extreme 3
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap.
06-17Free

Director

15,000 0.0207%
06-17Free

Director

15,000 0.0207%
06-17Free

Director

15,000 0.0207%
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%+7.04%+190.00%+76.76% 672M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.45%+6.37%+67.82%+139.55% 24.62B
Weighted average by Cap. +2.45%+6.42%+58.68%+136.80%

Financials

2026 *2027 *
Net sales 67.83M 59.3M 54.5M 50.8M 96.35M 6.46B 97.81M 654M 254M 3.17B 255M 249M 10.94B 143M 125M 115M 107M 203M 13.63B 206M 1.38B 537M 6.7B 537M 526M 23.08B
Net income 21.23M 18.56M 17.06M 15.9M 30.16M 2.02B 30.62M 205M 79.61M 994M 79.7M 77.99M 3.42B -47.25M -41.31M -37.96M -35.38M -67.11M -4.5B -68.13M -456M -177M -2.21B -177M -174M -7.62B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-07-02 US$9.280 -1.38% 1,375,685
26-07-01 US$9.410 -1.05% 1,429,453
26-06-30 US$9.510 -4.04% 1,945,049
26-06-29 US$9.910 +14.30% 2,744,125
26-06-26 US$8.670 -19.12% 10,918,913
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
9.280USD
Average target price
33.00USD
Spread / Average Target
+255.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock